PVT1 and MIR205HG expression levels were examined in 20 patients with lymph node-negative HNSCC (LN negative group) compared with that in 20 patients with lymph node-positive HNSCC (LN positive group) who were matched for treatment modality, TNM stage, pathological differentiation, location of the primary carcinoma, sex, and age. This evidence concerns the gene PVT1 and carcinoma.